Trial Profile
A prospective trial evaluating the safety and efficacy of Dianhydrogalactitol (VAL-083) in pediatric patients with medulloblastoma (MB) and high grade gliomas (HGG)
Status:
Suspended
Phase of Trial:
Phase I
Latest Information Update: 30 Nov 2023
Price :
$35
*
At a glance
- Drugs Dianhydrogalactitol (Primary)
- Indications Glioma; Medulloblastoma
- Focus Adverse reactions
- 31 Oct 2023 According to a Kintara Therapeutics media release, company is suspending the development of VAL-083 based on the topline preliminary safety results from GBM AGILE trial.
- 31 Oct 2023 Status changed from planning to suspended, according to Kintara Therapeutics media release.
- 07 Sep 2016 According to Del Mar Pharmaceuticals media release,VAL-083 has received orphan drug designation in the U.S.